Clinical trials for Acute Lymphoblastic Leukemia

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44346 clinical trials with a EudraCT protocol, of which 7374 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (555)
Paediatric studies in scope of Art45 of the Paediatric Regulation (79)

555 result(s) found for: Acute Lymphoblastic Leukemia. Displaying page 28 of 28.

EudraCT Number: 2007-006652-19

Sponsor Protocol Number: NILG-ALL 10/07

Start Date*: 2008-02-06

Sponsor Name:NILG

Full Title: A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxis with Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treat...

Medical condition: 2. Diagnosis of untreated ALL with B-/T-precursor phenotype or B/T-LL, either de novo or secondary to chemo-radiotherapy for other cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10005329	Blood and lymphatic system disorders	SOC

Population Age: Adults

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2004-001417-33

Sponsor Protocol Number: 20040156

Start Date*: 2004-10-19

Sponsor Name:Amgen Inc

Full Title: A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy

Medical condition: Chemotherapy induced anemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	7.0		10049105		PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) SE (Completed) FI (Completed) AT (Completed) CZ (Completed) GB (Completed) IT (Completed) DK (Completed)

Trial results: View results

EudraCT Number: 2007-004517-34

Sponsor Protocol Number: AMLSCT-BFM2007

Start Date*: 2010-01-13

Sponsor Name:Hannover Medical School

Full Title: Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML Multi Center Therapy Concept

Medical condition: Relapsed or refractory Acute Myeloid Leukemia (AML)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10000886	Acute myeloid leukemia	LLT
	20.0	100000004865	10067859	Allogenic stem cell transplantation	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: DE (Completed) CZ (Completed) AT (Completed)

Trial results: View results

EudraCT Number: 2020-005025-85

Sponsor Protocol Number: FT03CARCIK

Start Date*: 2021-04-02

Sponsor Name:FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS

Full Title: Measurable residual disease driven strategy for one or two infusions of non-viral, transposon-manipulated CARCIK-CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractor...

Medical condition: Refractory or relapsed acute B-cell lymphoblastic leukemia after haematopoietic stem cell transplantation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-002192-41	Sponsor Protocol Number: E:531/2011	Start Date*: 2012-02-09
Sponsor Name:University Hospital Tübingen
Full Title: Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation afte...
Medical condition: Treatment of patient with advanced hematologic malignancies such as patients with leukemia or lymphoma treatable by allogeneic stem cell transplantation but without a suitable matched donor.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results

EudraCT Number: 2011-001534-42

Sponsor Protocol Number: TrRaMM4Gy

Start Date*: 2011-10-21

Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR

Full Title: Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies

Medical condition: Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched fa...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10042613 - Surgical and medical procedures	10001756	Allogenic bone marrow transplantation therapy	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2017-004981-85

Sponsor Protocol Number: CD101.IV.3.08

Start Date*: 2020-04-06

Sponsor Name:Cidara Therapeutics, Inc.

Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults...

Medical condition: Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10021881 - Infections and infestations	10017528	Fungal infectious disorders	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2013-001418-13

Sponsor Protocol Number: TED10893

Start Date*: 2014-11-04

Sponsor Name:Sanofi-aventis recherche & développement

Full Title: A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hemat...

Medical condition: Haematological malignancy

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066476	Haematological malignancy	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) AT (Completed)

Trial results: View results

EudraCT Number: 2020-003452-32

Sponsor Protocol Number: CD19-CAR_Lenti

Start Date*: 2021-01-13

Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA

Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma...

Medical condition: relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10005329	Blood and lymphatic system disorders	SOC

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2009-010826-20	Sponsor Protocol Number: 2008_40	Start Date*: 2009-05-15
Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
Full Title: A phase I dose escalation study of clofarabine given in combination with multi-agent therapy for remission induction in pediatric patients with acute lymphoblastic leukemia in first relapse or refr...
Medical condition: Traitement de la leucémie aigue lymphoblastiqsue
Disease:
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults		Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003398-79	Sponsor Protocol Number: MH21HEM	Start Date*: 2023-05-11
Sponsor Name:Princess Máxima Center for pediatric oncology
Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...
Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...
Disease:
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2017-002054-37

Sponsor Protocol Number: 1000053649

Start Date*: 2019-09-18

Sponsor Name:Hospital for Sick Children

Full Title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers

Medical condition: HYPERMUTANT CANCERS

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10078672	DNA mismatch repair protein gene mutation	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10038111	Recurrent cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070308	Refractory cancer	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FR (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2014-000584-41

Sponsor Protocol Number: BP-004

Start Date*: 2014-10-23

Sponsor Name:Bellicum Pharmaceuticals, Inc.

Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders

Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10005329 - Blood and lymphatic system disorders	10018849	Haematological disorders NEC	HLGT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2016-004808-60

Sponsor Protocol Number: HD-CAR-1/V04

Start Date*: 2018-04-12

Sponsor Name:University Hospital Heidelberg

Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial

Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10063625	Acute lymphoblastic leukemia recurrent	LLT
	23.0	100000004864	10029595	Non-Hodgkin's lymphoma NOS refractory	LLT

Population Age: Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-000066-11

Sponsor Protocol Number: 114-022

Start Date*: 2018-09-17

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoie...

Medical condition: Pneumococcal disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10021881 - Infections and infestations	10061353	Pneumococcal infection	PT

Population Age: Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) FR (Completed) BE (Completed) SE (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon Jun 30 08:28:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA